Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Moodys
Colorcon
Harvard Business School
Healthtrust
Deloitte
Mallinckrodt
Farmers Insurance
Accenture

Generated: December 19, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CEFTAZIDIME

« Back to Dashboard

Clinical Trials for Ceftazidime

Trial ID Title Status Sponsor Phase Summary
NCT00173901 Adverse Drug Reactions of Different Brands of Ceftazidime Injection Unknown status National Taiwan University Hospital Phase 4 The purpose of this study is to understand whether generic ceftazidime causes different adverse drug reaction incidence from the brand drug.
NCT00210964 Ceftobiprole in Hospital Acquired Pneumonia Completed Basilea Pharmaceutica Phase 3 The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril (the water-soluble prodrug [form] of ceftobiprole) referred to as ceftobiprole versus a comparator in the treatment of patients with nosocomial pneumonia.
NCT00229008 Ceftobiprole in Hospital Acquired Pneumonia Completed Basilea Pharmaceutica Phase 3 The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril (the water-soluble prodrug [form] of ceftobiprole) referred to as ceftobiprole versus a comparator in the treatment of patients with nosocomial pneumonia.
NCT00333385 Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis Terminated Baxter Healthcare Corporation Phase 4 The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary PA infection. In conventional treatment regimens, ceftazidime is administered in the form of thrice daily short infusions, but pharmacodynamic considerations suggest that continuous infusion could be more effective.
NCT00333385 Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis Terminated GlaxoSmithKline Phase 4 The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary PA infection. In conventional treatment regimens, ceftazidime is administered in the form of thrice daily short infusions, but pharmacodynamic considerations suggest that continuous infusion could be more effective.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Ceftazidime

Condition Name

Condition Name for Ceftazidime
Intervention Trials
Cystic Fibrosis 4
Pneumonia 4
Healthy 3
Complicated Intra-abdominal Infection 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ceftazidime
Intervention Trials
Infection 14
Communicable Diseases 13
Urinary Tract Infections 7
Pneumonia 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ceftazidime

Trials by Country

Trials by Country for Ceftazidime
Location Trials
United States 80
Spain 11
India 11
Czech Republic 8
France 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ceftazidime
Location Trials
California 10
Ohio 8
Michigan 6
Florida 5
Texas 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ceftazidime

Clinical Trial Phase

Clinical Trial Phase for Ceftazidime
Clinical Trial Phase Trials
Phase 4 9
Phase 3 13
Phase 2/Phase 3 2
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ceftazidime
Clinical Trial Phase Trials
Completed 27
Recruiting 6
Unknown status 5
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ceftazidime

Sponsor Name

Sponsor Name for Ceftazidime
Sponsor Trials
AstraZeneca 17
Forest Laboratories 7
Basilea Pharmaceutica 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ceftazidime
Sponsor Trials
Industry 36
Other 33
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Moodys
Farmers Insurance
Dow
Queensland Health
Merck
US Army
US Department of Justice
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.